LEXINGTON, Mass., Nov. 12, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced that it will host an R&D Day on November 15, 2019.

- UroGen receives rights to zalifrelimab to be used in its proprietary sustained release formulation for patients with high-grade non-muscle invasive bladder cancer LEXINGTON, Mass., Nov. 11, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of

- PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies clear INDs & advance into clinical trials - NexGen CTLA-4 (AGEN1181) advances to 3rd cohort;

LEXINGTON, Mass., Oct. 31, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019.

LEXINGTON, Mass., Sept. 30, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced today that Jennifer Buell, PhD, Chief Operating Officer of Agenus, present an

FDA acceptance of IND filing for AGEN1223; triggers cash milestone AGEN1223 is a first-in-class bi-specific designed to deplete regulatory T cells in tumor microenvironment LEXINGTON, Mass., August 28, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a

Invented by Agenus, licensed to Gilead, GS-1423 is a bi-functional antibody designed to block tumor escape mechanisms Supply supports ongoing Phase 1 of GS-1423 in patients with advanced solid tumors LEXINGTON, Mass., August 21, 2019 / PRNewswire / -- Agenus Inc.

- FDA acceptance of IND filing for AGEN2373 triggers payment and clears path to begin clinical trials - The payment represents the second milestone in Gilead partnership achieved in 2019 LEXINGTON, Mass., Aug. 8, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O)

- Enrollment of CTLA-4 & PD-1 trials on track; data expected 2H2019 - Second generation CTLA-4 advances in clinic; data expected 2H2019 - Launched commercial readiness with head of commercial on board - $15M in cash milestones triggered; new compounds move towards clinic - GSK's Shingrix sales

LEXINGTON, Mass., Aug. 6, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens on Thursday, August 8, 2019.

LEXINGTON, Mass., July 18, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head

LEXINGTON, Mass., June 13, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stockholders

- Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - GSK's Shingrix sales continue to grow; projected to be ~$1.3Bn in 2019 LEXINGTON, Mass.

LEXINGTON, Mass., May 3, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market opens

LEXINGTON, Mass., April 2, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , today announced that the first patient was dosed in the  clinical trial  of its

- Dr. Manuel Hidalgo, MD, PhD as Strategic Advisor - Paulo Moreira as Global Head of Clinical Operations LEXINGTON, Mass., March 21, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell

- Gilead collaboration results in cash infusion of $150M; first milestone payment of $7.5M triggered - CTLA-4 & PD-1 trials are accruing for planned BLA filing as early as 2020 - Next-Gen CTLA-4 advancing - expect first patient to be dosed this month - First year revenues of GSK's SHINGRIX

- FDA has accepted IND filing for AGEN1423 LEXINGTON, Mass., March 13, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that the FDA has

LEXINGTON, Mass., March 8, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its fourth quarter and full year 2018 financial results before the market

-- Agenus Conference Call and Live Webcast Scheduled for 11:00a.m. ET today -- LEXINGTON, Mass., Feb. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1,

LEXINGTON, Mass., Feb. 15, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today that its Biotech Electronic Security Token (BEST), the first

- The Biotech Electronic Security Token (BEST) is designed to be an innovative and transformative way to finance drug development through increasing liquidity, minimizing dilution, and improving capital allocation - BEST democratizes financing through targeted investments for specific therapeutic

LEXINGTON, Mass., Jan. 24, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its immuno-oncology (I-O) partnership deal with Gilead Sciences,

- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21 - Grant to develop an alternative, novel plant cell-culture based method for QS-21 production LEXINGTON, Mass., Jan. 3, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a

-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET -- FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 / PRNewswire / -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O)